AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05883332 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Self-Administered Nitrous Oxide
Description: Nitrous oxide administered at concentrations of mild sedation (20-50%)
Study NCT05883332 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oxygen
Description: 100% oxygen at 10 Liters/minute
Study NCT06351098 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: nap
Description: Children are nap promoted
Study NCT06183372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lemon balm
Description: 300mg Lemon balm and Maltoxdextrin capsules Other Name: Melissa Officinalis L.
Study NCT06183372 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 300mg Maltodextrin capsules
Study NCT04763486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cefazolin (Cefamezin)
Description: Cefamezin 2 gr within 6 hour of delivery
Study NCT05425654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab, Methotrexate, Vincristine, Procarbazine, Lenalidomide
Description: The initial treatment will consist of cycles of 14 days. Each cycle will start with rituximab, which will be given by vein on day 1. On day 2 you will receive: Methotrexate will be given by vein over 2 to 3 hours and vincristine will be given as a single injection over a few minutes. Procarbazine and Lenalidomide are a pill that you will take at bedtime for 7 nights starting on day 2. Procarbazine and Lenalidomide are only given every other cycle. During each cycle, you will be in the hospital. After the second cycle of chemotherapy, PBPCs will be collected. You will be hospitalized again for high-dose chemotherapy and receive supportive medications to help avoid complications, including antibiotics and blood transfusions. Busulfan, carmustine and cyclophosphamide will be given to you for 5 days. After break of 1 day, we will return your PBPC (or bone marrow) to you through a vein. You will be in the hospital for at least 3 weeks.
Study NCT05832112 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS/RATS lobectomy
Description: Consenting patients will undergo lobectomy by OTC RATS following the exact standard steps usually done by VATS/RATS, aside from the ports that will be placed in the subcostal plane. The characteristics of both the patient and the case, will determine the number of incisions from 1-4.~The Davinci Xi® surgical system will be used to perform the lobectomy through the ports using the standard technique with an anterior approach. Once the procedure is completed, the robotic arms and ports will be removed from the chest and figure-of-8 stitches with non absorbable sutures will be placed to close the diaphragm at the site of insertion. A 24 Fr soft chest tube will be left in place, as in the standard VATS/RATS lobectomy procedure. The incision closure will be done in a standard manner.
Study NCT05899231 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation Programming
Description: 12-weeks of online prehabilitation programming including:~1.12 weeks of nutrition programming focused on achieving a guideline- based protein intake of 1.2-1.5 g/kg/day. Participants will participate in a dietitian assessment and 0-2 dietitian follow-ups stratified by risk and 5 virtual group nutrition classes. Participants will be provided with a whey protein powder supplement - dosing stratified by risk.~2.10 weeks of exercise programming focused on completion of 3 full- body resistance/aerobic exercise sessions weekly (1 or 2 virtual group classes as per patient preference + 1 or 2 pre-recorded home exercise videos).~3.12 weeks of acceptance and commitment therapy based educational videos and online activities focused on reducing stress and anxiety and improving motivation and adherence.
Study NCT03960125 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photodynamic Therapy
Description: Blue Light Therapy Exposure
Study NCT03960125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% Imipramine
Description: A tricyclic antidepressant (TCA) medication. Though it is usually taken orally, topical preparations (4%) has use in topical anesthetics and anti-pain medicaments.
Study NCT03960125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Base Cream
Description: Control to 4% Imipramine
Study NCT06174467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SEELearning Training
Description: This group will receive the Learning Training for Hearts and Minds and will be submitted to assessments and questionnaires that measure the improvement of well-being, reduction of stress and literacy in the contents and human values taught in the training.~The program aims to increase participants' awareness, compassion and engagement. Compassion refers to cultivating a way of relating to oneself, others and humanity through kindness, empathy and genuine care for the happiness and suffering of these individuals. Awareness refers to cultivating a detailed, first-person understanding of thoughts, feelings, and emotions.
Study NCT06174467 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waiting list group of the intervention
Description: The group will remain on a waiting list and will respond to questionnaires about well-being and other items before receiving the training and, in the second semester, during the period in which it will receive the training
Study NCT05635032 — intervention group
Intervention type: OTHER
Intervention: Comprehensive clinical assessment and biological samples collection
Description: To establish the first Portuguese registry and biobank of PF-ILDs, comprising both extensive patient-level data, and systematic biological sampling (DNA, RNA, plasma, serum, bronchoalveolar lavage, lung tissue) at baseline and repeated biological sampling of blood and pharyngeal swabs performed at 6, 12 and 18 months, or whenever progression criteria are met or an acute exacerbation occurs. Participants will have regular visits at maximum intervals of 6 months, when their clinical condition and lung function tests are reassessed. A high resolution computed tomography (HRCT) scan of the lung will be performed every 12 months. Progressive fibrosis will be diagnosed based on meeting at least two of the following three criteria, occurring within the last year: (i) worsening of symptoms; (ii) absolute decline in FVC ≥5% predicted or absolute decline in DLCO (corrected for Hb) ≥10% predicted; (iii) increased extent of fibrotic changes on HRCT.
Study NCT06197165 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Targeted Shiatsu
Description: demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu
Study NCT06197165 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Targeted Shiatsu
Description: demonstrate the beneficial impact targeted Shiatsu compared with a comfort Shiatsu
Study NCT06107803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Roluperidone 64 mg
Description: 64 mg/day oral
Study NCT05305742 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Instrument Design
Description: Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
Study NCT05305742 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Design
Description: Research the effect of different instrument designs on root canal preparation by evaluating bacterial count reduction and post-operative pain
Study NCT06107803 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine 10 MG
Description: 10 mg/day oral
Study NCT06282783 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Description: Single dose of 400mg
Study NCT06551766 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photosensitive hydrogel
Description: In the photosensitive hydrogel group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by photosensitive hydrogel.
Study NCT06551766 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 6-0 absorbable stitches
Description: In the suture fixation group, the anastomosis of the lacrimal cyst mucosal flap and the nasal mucoperiosteal flap was achieved by two stitches using 6-0 absorbable wire.
Study NCT05998148 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: virtual phone appointment visits
Description: Patient will have post-operative appointments that place with telemedicine. The visits will will be virtual phone appointments scheduled at approximately 6 weeks, 12 weeks, and 6 months after surgery.
Study NCT04976413 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Eye Movement Desensitization and Reprocessing (EMDR) psychotherapy
Description: Experimental arm will receive eight phase EMDR treatment using manualized standard protocol. Selection of targets for reprocessing through EMDR will be made according to adaptive information processing model's postulations, that links traumatic events with the symptoms of depression and anxiety. Time period allocated to EMDR treatment is 12-14 weeks.
Study NCT04976413 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Counselling as usual
Description: Control arm will receive counseling as usual for 12-14 weeks
Study NCT05198518 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microcurrent TENS device
Description: The study device is a handheld micro-current TENS emitter intended to be used for the relief of postoperative pain after FESS. The design of the study device was optimized to provide transcutaneous nerve stimulation to the regional areas associated with the sinuses.
Study NCT05198518 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Device
Description: The sham device appears and operates identically to the active device, including indicator lights and haptic vibration, however it emits a weak direct current that is non-therapeutic.
Study NCT05232812 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3-[11C]-OHB
Description: The PET tracer 3-\[11C\]-OHB is used to quantify 3-hydroxybutyrate uptake
Study NCT04368689 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Floatation-based reduced environmental stimulation therapy
Description: Completion of 3 float session that can last for up to 90 minutes each session, each spaced approximately one week apart
Study NCT05529446 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Combination therapy (CT)
Description: Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
Study NCT05529446 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Combination therapy (CT)
Description: Two therapeutic modalities at the same site is described as combination therapy (CT). The most commonly used CT is US \& TENS where this approach was effective in pain modulation
Study NCT06358235 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music Therapy
Description: 30-minute music therapy session.
Study NCT06358235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Music therapy
Description: The practice where patients are simply fitted with headphones and rest quietly without listening to music.
Study NCT06434623 — intervention group
Intervention type: OTHER
Intervention: patient record
Description: using patient record to construct AI models
Study NCT05184543 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine Exercise Program
Description: 8 weeks of routine basketball training will be done. Dynamic stretching exercises, in which large muscle groups are exercised, can be applied for 20 minutes.
Study NCT05184543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability Exercise Program
Description: In addition to the 8-week routine basketball training, 20 min core stability exercises will be given to the Core Group. Core stability exercises will be performed on the stable surface for the first 4 weeks, and core stability exercises will be performed on unstable surfaces for the next 4 weeks.
Study NCT05184543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body Weight Neuromuscular Warm-Up Program
Description: Each 20-minute program consists of 5 different parts. The beginning of the program consists of low-speed running exercises with the ball. The running track for each exercise will include 4 basketball court areas. The second part consists of active stretching exercises. The third part consists of exercises focusing on general strength. The fourth part consists of plyometric, balance, and jump exercises. The final section consists of a sprint with sudden changes of direction and basketball movements.
Study NCT03763357 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy (HT)
Description: Water at 42-43 degrees C will be circulated through the water circulating trousers to obtain calf skin temperature 39 degrees C followed by PET/CT imaging of generator-based 62Cu-ETS.
Study NCT05329324 — intervention group
Intervention type: OTHER
Intervention: Questionnaire for study group
Description: Demographic features, Stage and Type, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
Study NCT05329324 — intervention group
Intervention type: OTHER
Intervention: Questionnaire for control group
Description: Demographic features, The LANSS Pain Scale and Pain Detect Questionnaire to assess patients' pain characteristics,the Nottingham Health Profile to assess quality of life, and the Hospital Anxiety and Depression Scale to detect the presence of depression and anxiety will be completed by patients.
Study NCT05344339 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Distal gastrectomy
Description: Reconstruction after Distal Gastrectomy
Study NCT05344339 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal gastrectomy
Description: Reconstruction after Distal Gastrectomy
Study NCT06218576 — intervention group
Intervention type: OTHER
Intervention: None, purely observational study
Description: None, purely observational study
Study NCT04920721 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention descriptiv study
Study NCT05384535 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Bi-parametric MRI
Description: When used for the evaluation of prostate cancer, MRI typically involves multiple sequences and typically includes typical T1 and T2 phases with the addition of diffusion weighted imaging and dynamic contrast enhanced imaging. In this study, we have decided to omit dynamic contrast enhanced imaging due to its decreased diagnostic yield relative to T2 and DWI and associated increased risk of contrast agents, this is a common approach for prostate cancer screening and is referred to as a bi-parametric MRI
Study NCT04864132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 6-minute walk test
Description: This test assesses submaximal exercise capacity.
Study NCT04864132 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Incremental shuttle walk test
Description: This test assesses maximal exercise capacity.
Study NCT05575505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pentoxifylline 400 MG
Description: Pentoxifylline (PTX) is a methyl-xanthine derivative that possesses antioxidant and anti-inflammatory characteristics
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia with slow decline in plasma glucose in type 1 diabetes
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Slow plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia with rapid decline in plasma glucose in type 1 diabetes
Description: Acute plasma glucose decline, divided into the following three phases: 1) Hyperglycaemic phase (plasma glucose 15 mmol/l), 2) Rapid plasma glucose decline phase and 3) Euglycaemic phase (plasma glucose 4.5-5.5 mmol/l).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound hyperglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L)
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rebound euglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in euglycemia (PG: 5-8 mmol/L).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in type 1 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (5-8 mmol/L), 2) hyperinsulinemic hypoglycemic phase (PG: 2.5 mmol/L), 3) recovery phase in hyperglycemia (20.0 mmol/L) or euglycemia (PG: 5-8 mmol/L)
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in type 2 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypoglycemia in healthy controls
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia in type 2 diabetes
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
Study NCT05500352 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hyperglycemia in healthy controls
Description: Includes three steady state phases in plasma glucose, 1) euglycemic phase (fasting PG), 2) hyperglycemic phase (fasting PG + 10 mmol/L), 3) hyperinsulinemic hypoglycemic phase (PG \< 3.0 mmol/L).
Study NCT05585710 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulsed Lavage Washout
Description: Use of pressurized, pulsed triple antibiotic solution to irrigate mastectomy pocket
Study NCT06634433 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Personnel Attitude
Description: The intervention consists of a two-phase Training of Trainers Program (TTP) designed for health professionals aimed at enhancing interprofessional education (IPE) skills. Phase 1 includes three days of online theoretical training, focusing on topics such as interprofessional collaboration, communication, and conflict resolution. Phase 2 involves two days of face-to-face practical sessions, where participants engage in scenario-based learning and small group discussions to apply IPE concepts. The effectiveness of the program is assessed through pre-test and post-test evaluations, measuring changes in participants\&#39; knowledge, attitudes, and competencies in interprofessional education.
Study NCT05585710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Implant-based breast reconstruction
Description: Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
Study NCT05585710 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implant-based breast reconstruction
Description: Standard of care; use of triple antibiotic solution delivered via bulb syringes to irrigate mastectomy pocket
Study NCT05585710 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral or unilateral mastectomy
Description: Standard of care
Study NCT04880473 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PrevisEA device
Description: The PrevisEA device is placed and activated on the patient's abdomen immediately post-op (within 1 hour of the completion of surgery) and maintained in position for at least 12 hours, counting the number of times MH4 is detected within a four-minute period at hourly intervals. The device determines the MH4 biomarker counts at each hourly collection point and the data are stored on the device. Under normal conditions, transformations of the data are visualized on the display. For this clinical trial, the display is obscured. Therefore, no value will be displayed for interpretation since this is a non-intervention trial and the device is not intended to affect or influence the standard of care for study participants.
Study NCT04311671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxidectin
Description: 2 mg tablets, encapsulated for blinding
Study NCT04311671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ivermectin
Description: 3 mg tablets, encapsulated for blinding
Study NCT04311671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole
Description: 400 mg tablets
Study NCT04311671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albendazole
Description: 400 mg tablets